downgrad ew stock close
price target
downgrad ew stock approach pt
leav estim pt unchang still see bull
case upsid busi stronger expect
disappoint result slower growth
downgrad equal-weight see balanc risk reward
current price level unchang price target current
stock price see risk/reward profil balanc upsid
bull case valuat includ growth upsid plu downsid
bear case valuat driven demand weak slow growth
solid compani fundament off-set fair valuat zoeti perform
well past year ytd past month
forward price-to-earnings multipl high also toward high end histor
see potenti modest upward pressur number given
strong momentum moder growth time revenu
margin con manag guidanc rang
midpoint ep con
guidanc rang midpoint high growth year
part due fx percentag point estimate revenue growth margin expans
effici step tax rate note due tougher comp
project moder growth yoy revenue growth
yoy ep growth approx beyond
compound-annual-growth-rate revenue growth ep growth
could wrong could continu outperform strong growth
rise multipl manag may util zoeti solid cash flow
strong balanc sheet pursu value-enhanc small-mid size deal
may like substanti anim health consolid transact
zoeti global market share could result anti-trust constraint
 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
base case ep current price-to-earnings premium vs
average sinc ipo project ep compound-annual-growth-rate
bull case ep
bull case ep
new product upsid drive faster revenu growth project zoeti
pursu value-enhanc organ ep upsid plu upsid
yield ep forecast
base case ep
base case ep
project double-digit ep growth driven growth companion
anim livestock project compound-annual-growth-rate revenu growth ep
compound-annual-growth-rate industri growth plu zoeti global roll-out
new product give us confid project
bear case ep
bear case ep
face lower end-market growth greater competit pressur drive
weak financi result share trade compani miss ep estimate
price-to-earnings multipl contract
rate zoeti equal-weight balanc
project organ revenu growth
ep growth
strong fundament balanc fair
top-lin growth oper margin
livestock rev demand
meat milk project least doubl
next year due larg part
popul growth increas
affluenc emerg market
companion anim rev
global spend pet grow
quarterli result guidanc updat
new product ramp rel
zoeti becom activ deploy
capit acquir products/compani
competitor perform better/wors
risk achiev price
long-term margin expans fail
new govern regul legisl
impact growth
dollar strength rel foreign
us specialti brand gener
spec brand gx mean
spec brand gx median
price
price
thomson reuter morgan stanley research estim valuat methodolog risk associ price target referenc research report pleas contact client support follow
us/canada hong kong latin america london singapor sydney tokyo altern may
contact invest repres morgan stanley research broadway attent research manag new york ny usa
exhibit consensu ntm price-to-earnings vs spec pharma average rel price-to-earnings expand due
enhanc percept rel durabl
exhibit incom statement margin valuat
sg op exp
sg sale
 sale
short-term invest
a/p accru liabil
total liabil s/e
chang work capit
oper
invest
net chang debt
financ
net chang cash
